An underground market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, according to recent findings.
Investigational Treatment Gaining Popularity Online
Retatrutide, which remains in research studies, is being advertised by online personalities for its alleged weight-reducing effects. Followers are encouraged to contact these accounts directly for supplier links, while also obtaining promotional offers.
Thriving Trade on Social Networks
Separately, a flourishing market exists on messaging services, where groups with thousands of participants share comparison images, administration instructions and assertions of rapid British shipping. Sellers promote the substance there before directing customers to other platforms for transactions.
Understanding The Experimental Drug
This medication is an investigational injection developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, GIP and glucagon. Early trials indicate it could assist individuals lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.
Medical Experts Voice Concerns
However, doctors and chemists have cautions that the distribution of what remains an unlicensed medication in the UK is worrisome and could lead to individuals injecting substances of unknown origin.
Several professionals said the popularity for the experimental drug could be connected to the increasing price of licensed weight loss treatments such as Mounjaro.
Regulatory Position and Implementation
Marketing the unapproved drug on TikTok or messaging apps is prohibited in the UK, as it is an unlicensed medication that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.
Some content creators attempt to sidestep the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but promotion and supply can still violate pharmaceutical, marketing, and consumer regulations, potentially leading to penalties, prosecution or imprisonment.
Service Reaction and Content Elimination
Based on the social media company, the service has removed violative content and prohibited related hashtags and query recommendations. The company stated it was dedicated to maintaining the platform secure and allocating resources in strengthening compliance measures.
Online Trading Activities
Research also discovered groups with up to 9,000 participants selling retatrutide using the platform's integrated search feature, which functions like a public directory. Typing “retatrutide” instantly brings up groups with numerous of users, filled with photos of weight loss, positive testimonials and detailed guides for preparing or injecting at home.
Within minutes of entering one group, a seller shared WhatsApp details, where most transactions occur. The seller provided an guidebook and promised shipping within 48 hours. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one inquired about body mass, health issues or previous experience.
Product Details and Costs
Within these groups, messages show black plastic parcels with postal service labels, stating to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at residence with sterile water, or ready-to-use pens typically sold at £160 for 20mg. When asked how much time a injector should last, vendors give contradictory responses ranging from a few weeks to “depends on your body”.
Platform Moderation and Safety Actions
A representative for Telegram stated it actively monitored harmful content on its service including content that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are injecting substances they can’t verify. Even if the science behind this drug is sound, these online versions may not contain what they advertise,” stated Jason Murphy, the director of pharmacy at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the surge in demand to recent price rises for approved slimming medications such as Mounjaro. “With prices rising, patients are turning to social media. But counterfeit injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.
Her staff has already seen individuals injured by personal administration from unconfirmed suppliers. “We understand the frustration, but buying from Telegram or communication platforms is gambling with your well-being,” stated the doctor. “These substances could be contaminated or incorrectly dosed.”
Producer Position
A representative from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this time no one can market [it] for human use,” they said, adding that any product “misleadingly claiming itself as a company investigational product not yet approved … may subject users to possibly serious health risks”.
